1. Introduction {#s0005}
===============

Osteogenesis imperfecta (OI) is a clinically and molecularly highly heterogeneous group of inherited bone disorders whose phenotype ranges from barely detectable to perinatal lethal. It occurs worldwide without gender preference and with an estimated incidence of 1/10,000 live births. OI, also known as "brittle bone disease", is prevalently characterized by low bone mass, skeletal deformities, bone fragility and growth deficiency [@bb0005].

The majority of OI cases (85--90%) have dominant transmission and are caused by structural or quantitative mutations in the *COL1A1* and *COL1A2* genes, which respectively encode α1(I) and α2(I) chains of type I collagen: the major structural protein of bone, skin and tendon extracellular matrix (ECM). For many years, OI has been considered a collagen disease and it was classified, according to clinical and radiological criteria, in four different types (I to IV) [@bb0010].

Since 2006, also autosomal recessive OI forms (10--15%) have been discovered. These are due to mutations in non-collagenous genes whose protein products are involved in type I collagen post-translational modification, folding, intracellular trafficking and extracellular matrix incorporation [@bb0015], [@bb0020], [@bb0025]. More recently, other mutations causative of recessive and X-linked OI have been described in genes that do not code for collagenous or collagen-handling proteins, but rather for proteins involved in osteoblast differentiation and bone mineralization [@bb0030], [@bb0035]. OI is now defined as a collagen-related disorder whose classification is based on the altered intracellular or extracellular metabolic pathways important for bone development [@bb0025], [@bb0035], [@bb0040].

Recessive OI types VII, VIII and IX, belonging to the group of OI forms caused by defects in collagen post-translational modification and folding [@bb0025], are linked to mutations in *CRTAP* (coding for cartilage-associated protein \[CRTAP\]), *P3H1* (coding for prolyl 3-hydroxylase 1 \[P3H1\]), which was until 2014 reported as *LEPRE1* (for more details see the "Osteogenesis imperfecta variant database", <https://oi.gene.le.ac.uk/>), and *PPIB* (coding for cyclophilin B \[CyPB\]) genes, respectively [@bb0015], [@bb0020], [@bb0045]. CRTAP, P3H1 and CyPB associate in 1:1:1 ratio to form, in the rough endoplasmic reticulum (rER), a complex that is responsible for the 3-hydroxylation of α1Pro986 residue in unfolded α1 chains of collagen type I [@bb0050], [@bb0055].

Up to date, the biological significance of 3-hydroxylated α1Pro986 has not been completely understood: while on one hand it is thought to facilitate the formation or stabilization of collagen trimers [@bb0060], on the other one, it has been suggested to destabilize the collagen triple helix [@bb0065]. In addition, the complex was also described to function as a chaperone and to prevent type I collagen chains from forming premature aggregates [@bb0050].

CRTAP is a helper non-enzymatic protein whose presence is required for the *in vivo* functionality of the 3-hydroxylation complex [@bb0015]. Despite most of this protein is located in the ER, a small amount of CRTAP is secreted in ECM, where its biological function is still unknown [@bb0070]. P3H1 is the enzymatic component of the complex that catalyzes the prolyl 3-hydroxylation reaction [@bb0075]. An isoform of P3H1 is secreted as leprecan, a chondroitin sulfate proteoglycan of the ECM [@bb0080].

The last component of the complex, CyPB, is an ER peptidyl-proyil *cis*-*trans* isomerase (PPIase), from the immunophilin family [@bb0085], that is responsible for the *cis*-*trans* isomerization of peptidyl-prolyl bonds, a rate-limiting step for collagen folding [@bb0090]. CyPB also acts as a member of many foldase and chaperone complexes, including BIP, GRP94, PDI, calreticulin, and calnexin, some of which we previously found deregulated in the Brtl^−/+^ knock-in murine model of dominant OI [@bb0095].

Mutations in *CRTAP* or *P3H1* genes cause absence or a severely reduction in α1Pro986 3-hydroxylation levels [@bb0100]. In particular, null mutations in either *CRTAP* or *P3H1* result in the absence of both proteins from mutant cells, indicating mutual stabilization of CRTAP and P3H1 in the complex [@bb0105]. According to the delay in collagen folding, CRTAP and P3H1 deficiency indirectly causes the over-modification of type I collagen α chains and their consequent intracellular retention [@bb0100]. On the contrary, CyPB expression is independent from protein levels of the other two components of the complex. Nonetheless, in *PPIB*-null cells CRTAP and P3H1 abundance is moderately reduced, as a probable consequence of delay in complex stability [@bb0020], [@bb0105]. In the absence of CyPB, 3-hydroxylation of α1Pro986 is actually merely reduced [@bb0110] or normal [@bb0020], and collagen α chains over-modification is not detectable in all cases. These observations suggest that CyPB may not be the only PPIase contributing to proper collagen folding [@bb0020].

Although there are distinctive features, OI types VII, VIII and IX phenotypically overlap dominant types II and III. The clinical features of *CRTAP* and *P3H1* mutant patients are consistently similar and include very low bone mineral density, rhizomelia, severe undertubulation of long bones, gracile ribs, neonatal fractures, growth deficiency, near normal head circumference, white or light blue sclerae. OI patients carrying CyPB defects lack rhizomelia [@bb0110].

Despite OI mainly affects bone tissue, skin outcomes have been proved both in patients and in murine models [@bb0115], [@bb0120], [@bb0125]. Skin quantitative magnetic resonance microimaging and histological analysis have recently been proposed as tools for less invasive OI diagnosis [@bb0130], [@bb0135]. Previously, we demonstrated consistent similarities in cellular pathway affection between bone and skin specimens in the Brtl^−/+^ mouse, model for dominant OI [@bb0095], [@bb0140]. Such alterations were also detected in primary fibroblasts of dominant OI patients [@bb0145].

Using a functional proteomic approach, we attempted to gain new insights into biochemical mechanisms and molecular pathways affected by recessive OI type VII, VIII, or IX. Performing 2-DE and image analysis, significant differentially expressed proteins were detected among the three tested forms of recessive OI and among them and control fibroblasts. Mass spectrometry (MS) identified protein-differences resulted principally involved in cytoskeletal and nuclear organization and development, protein fate, and metabolism. To interpret the functional molecular meaning of such aberrances in protein abundance, we processed the identified proteins by the MetaCore pathway analysis software. The overwhelming majority of MS identified proteins were tightly functionally cross-linked thus stressing the high probative value of our data and suggesting their actual involvement in OI. Particularly, heat shock protein beta-1 (HSP27), pyruvate kinase PKM (PKM2), lamin A/C, serine/threonine-protein kinase PAK 2 (PAK2), and protein S100A4 (MTS1), which are known to be involved in cell proliferation, cytoskeleton and nuclear lamina organization, and in osteogenesis, resulted the main central hubs of the net.

Based on our previous findings concerning deregulation of cytoskeleton in dominant OI, we focused our attention on nuclear lamina and actin cytoskeleton organization and we proved their consistent disorganization in *CRTAP*, *P3H1* and *PPIB* mutant fibroblasts.

According to our data, cytoskeleton and nucleoskeleton emerged as possible novel therapeutic targets in OI.

2. Material and methods {#s0010}
=======================

2.1. Human fibroblasts {#s0015}
----------------------

Human fibroblasts from skin biopsy of four controls, three OI patients with mutations in the *CRTAP* gene, three OI patients with mutations in the *P3H1* gene and one patient with a mutation in the *PPIB* gene were obtained after informed consent and used up to passage P10.

All patients were diagnosed with severe/lethal OI and their mutations were previously reported in [@bb0015], [@bb0150], [@bb0155], [@bb0160]. The detailed clinical outcome of one *P3H1* mutant patient, which was compound heterozygous for two causative mutations previously identified in different OI cases [@bb0165], [@bb0170], will be described elsewhere.

Cells were grown at 37 °C in humidified atmosphere containing 5% CO~2~ and cultured in Dulbecco Modified Eagle\'s Medium (D-MEM) supplemented with 10% (v/v) Fetal Bovine Serum (FBS), 4 mM glutamine, 100 μg/ml penicillin and 0.1 mg/ml streptomycin. For each experiment 2.5 × 10^4^ cells/cm^2^ were plated and harvested after 5 days.

2.2. Sample preparation for 2-DE analysis {#s0020}
-----------------------------------------

Cells were lysed in the following 2-DE lysis buffer: 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 1% (w/v) dithioerythritol (DTE). Samples were sonicated on ice for 2 min, vortexed and then centrifuged at 15,000 ×* g* for 5 min at 4 °C. The supernatants were recovered and, after estimation of protein concentration by Bradford\'s assay [@bb0175], they were aliquoted and stored at − 80 °C, until use.

2.3. 2-DE {#s0025}
---------

2-DE was performed using the Immobiline-polyacrylamide system, as previously described [@bb0180], [@bb0185]. IEF was carried out on non-linear wide-range immobilized pH gradients (IPG) (pH 3--10; 18 cm long IPG strips; GE Healthcare, Uppsala, Sweden) and performed using the Ettan™ IPGphor system (GE Healthcare). Strips for analytical runs were rehydrated with 350 μl of lysis buffer containing bromophenol blue in trace and 0.2% (v/v) carrier ampholyte, for 12 h at room temperature. Sixty micrograms protein, diluted in 100 μl of lysis buffer with bromophenol blue in trace, was loaded at the cathodic end of the strip by dedicated cups, and the run was performed using the Manifold Tray for Ettan™ IPGphor™ (GE Healthcare). Proteins were focused, at 16 °C, according to the following voltage steps: 200 V for 8 h, from 200 V to 3500 V in 2 h, 3500 V for 2 h, from 3500 V to 5000 V in 2 h, 5000 V for 3 h, from 5000 V to 8000 V in 1 h, 8000 V for 3 h, from 8000 V to 10,000 V in 1 h, 10,000 V until a total of 93,000 Vh was reached.

MS-preparative strips were rehydrated with 350 μl of lysis buffer containing traces of bromophenol blue and 2% (v/v) carrier ampholyte, for 12 h at room temperature. Sample load, 600 μg protein per strip, was performed by cup-loading at the cathodic end of the strip, and IEF was achieved in the Manifold Tray for Ettan™ IPGphor™ (GE Healthcare) by applying the same voltage protocol of analytical runs and by reaching a total of 100.000 Vh.

After IEF, analytical and MS-preparative strips were equilibrated for 12 min in 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.05 M Tris--HCl pH 6.8, 2% (w/v) DTE; and for further 5 min in the same equilibration buffer except for 2% (w/v) DTE that was substituted with 2.5% (w/v) iodoacetamide. Bromophenol blue was used as tracking dye.

The second dimension was carried out, at 10 °C, on house-made 9--16% polyacrylamide linear gradient gels (18 cm × 20 cm × 1.5 mm) at 40 mA/gel constant current, until the dye front reached the bottom of the gel.

Analytical and MS-preparative gels were stained with ammoniacal silver nitrate [@bb0190], [@bb0195] and with a MS-compatible silver staining procedure [@bb0200], respectively. All gels were scanned using the ImageScanner III (GE Healthcare).

2.4. Image analysis and statistics {#s0030}
----------------------------------

A 2-D spot map was obtained for each fibroblast sample, and the corresponding image analysis was carried out using the ImageMaster 2D Platinum v. 6.0 software (GE Healthcare). An intra-class analysis was performed by comparing the gels from the same condition. In order to detect any statistically significant quantitative and qualitative difference occurring among them, a differential inter-class analysis was done comparing, at the same time, all the 4 classes. Protein spots that showed at least ± 2 fold change in relative volume (%V) ratio, among the four conditions, at a 95% confidence level (1-way ANOVA: p ≤ 0.05), were considered significant differences. Pair-wise comparison of experimental groups was also performed for the significant differences that were selected according to above applied parameters by the Tukey\'s post-hoc multiple comparison test using the Excel Template inerSTAT-a v. 2.0.

The distribution of differentially expressed proteins among the six performed pair comparisons was visualized by a six-way Venn diagram that was obtained using the freely accessible jvenn software (<http://bioinfo.genotoul.fr/jvenn/example.html>) [@bb0205].

2.5. Protein identification {#s0035}
---------------------------

Differentially expressed spots were manually excised from MS-preparative gels, destained [@bb0210], and dehydrated in acetonitrile. After spot rehydration in trypsin solution (Sigma Aldrich, St. Louis, MO), in-gel protein digestion was performed by an overnight incubation at 37 °C. From each protein digest, 1.25 μl of tryptic-peptide solution was directly spotted onto the MALDI target and air-dried. Then, 0.75 μl of matrix solution (5 mg/ml alpha-cyano-4-hydroxycynnamic acid in 50% (v/v) acetonitrile and 0.5% (v/v) trifluoroacetic acid) was added to the dried samples and allowed to dry again. Mass spectra were acquired using an Ultraflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Billerica, MA), equipped with a 200 Hz smartbeam™ I laser, in reflector positive mode with a laser frequency set to 100 Hz. Spectra were analyzed by Flex Analysis software v. 3.0. Mascot (Matrix Science Ltd., London, UK, <http://www.matrixscience.com>) PMF database searching was carried out in Swiss-Prot database (version 2016_11; 553,231 sequences; 197,953,409 residues) set for *Homo sapiens*. The experimental and theoretical peptide fingerprinting patterns Δmass was \< 100 ppm, and trypsin was selected as the digestion enzyme with one allowed missed cleavage. Alkylation of cysteine by carbamidomethylation was assumed as fixed modification and oxidation of methionine as a possible one. The parameters used to accept identifications were the number of matched peptides, the extent of sequence coverage, and the probabilistic score.

Peptide digests that did not give unambiguous identifications were further analyzed performing MS/MS, using the same mass spectrometer. Two/three PMF peaks showing a high intensity were CID fragmented using Argon as collision gas, and MALDI-TOF/TOF tandem MS was performed in LIFT mode by software controlled data acquisition. Fragmented ions were analyzed using the Flex Analysis software v.3.0. The MS/MS database searching was carried out in the Swiss-Prot database (version 2016_11; 553,231 sequences; 197,953,409 residues) using the on-line available MASCOT MS/MS ion search software. The parameters applied for database searching were: *Homo sapiens* for taxonomy, trypsin specificity, one missed cleavage allowed, ± 100 ppm as peptide precursor mass tolerance, ± 0.6 Da allowed fragment mass tolerance, + 1 as peptide precursor charge state, carbamidomethylation of cysteine and oxidation of methionine as fixed and possible modifications, respectively. Mascot ion score, peptide coverage by "b" and "y" ions, and expected value were considered for protein identification.

2.6. Functional analysis {#s0040}
------------------------

Differentially expressed proteins were subjected to unsupervised hierarchical clustering (HC): firstly, according to their expression levels in the 4 different tested conditions, and then, basing on their functional description by Gene Ontology (GO) terms. The former HC analysis was done using Cluster 3.0, an open source clustering software (<http://bonsai.hgc.jp/~mdehoon/software/cluster/index.html>) [@bb0215], that clusters proteins of interest according to their expression similarities. Relative volume (%V) mean values of significant differentially expressed proteins, that were computed in spot maps from control cells, *CRTAP*, *P3H1*, and *PPIB* fibroblasts, were normalized and loaded into Cluster 3.0 software. HC expression matrix was computed using Absolute value of centered correlation distance (Pearson) and complete linkage. The clustering results were indeed visualized by the open source tool Java TreeView [@bb0220].

Functional HC was performed using the DAVID (Database for Annotation, Visualization and Integrated Discovery) bioinformatics resource v. 6.7 (<http://david.abcc.ncifcrf.gov>) [@bb0225]. The list of UniProtKB accession numbers of unique MS identified differentially expressed proteins was processed through the DAVID functional annotation tool according to Gene Ontology (GO) terms. Protein functional classes were obtained by DAVID clustering and according to literature text mining. The main resulting significant classes were then visualized using an histogram from a five-way Venn diagram obtained by the freely accessible jvenn software [@bb0205].

To proceed in functional investigation, MS identified proteins were analyzed by pathway analysis using the MetaCore network building tool (GeneGo Inc., St. Joseph, MI), which operates basing on an in-house manually annotated database of protein interactions and metabolic reactions from scientific literature. Proteins of interest were imported into MetaCore and processed using the shortest path algorithm that allowed to introduce into the net a maximum of one protein, not included among the experimental proteins, to interconnect experimental factors. Hypothetical generated networks were indeed prioritized according to their statistical significance (p \< 0.001) and graphically visualized by hubs (proteins) and edges (the relationships between proteins).

2.7. Western blotting {#s0045}
---------------------

For 1-D western blots, protein extracts from all control and pathological fibroblasts were obtained in presence of the Laemmli buffer: 100 mM Tris--HCl pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 4% (v/v) β-mercaptoethanol, and heated at 95 °C for 5 min [@bb0230]. For each sample, 25 μg of proteins was subjected to SDS-PAGE and electroblotting, as previously described [@bb0095]. For 2-D western blots, whole fibroblast lysates from control subjects and from *CRTAP*, *P3H1*, and *PPIB* mutant patients were obtained using a conventional 2-DE lysis buffer: 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 1% (w/v) DTE. For each tested condition, 120 μg of proteins was subjected to IEF and SDS-PAGE according to the same procedure used for the 2-D analytical runs. 2-D electroblotting experimental procedure was the same described in [@bb0095].

The immunodetection was achieved applying the protocol previously reported [@bb0095] and using the following antibodies: rabbit polyclonal anti-lamin A/C (sc-20681) from Santa Cruz Biotechnology (San Jose, CA, USA), 1:1000 diluted; rabbit monoclonal anti-cofilin (D3F9) from Cell Signaling Technology (Danvers, MA, USA), 1:1000 diluted; and polyclonal goat anti-rabbit IgG secondary antibody (A0545) from Sigma-Aldrich (Saint Louis, MO, USA), 1:7000 diluted. Immunoreactive bands were visualized by chemiluminescence using ECL detection reagents (GE Healthcare). Chemiluminescent signals were captured by ChemiDoc™ imaging system (Bio-Rad). The obtained 1-D and 2-D western blot images were then analyzed with the ImageQuant v. 3.0 software (Molecular Dynamics World Headquarters, Sunnyvale, CA) and the ImageMaster 2D Platinum v. 6.0 software, respectively. For 1-D western blot, β-tubulin immunoblotting ensured equal loading of samples in each lane. Rabbit polyclonal anti-β-tubulin (sc-9104) from Santa Cruz Biotechnology (San Jose, CA, USA), 1:1000 diluted, was used.

2.8. Immunofluorescence analyses {#s0050}
--------------------------------

For lamin staining, cells were fixed with cold 100% CH₃OH for 15 min, washed with PBS and blocked 1 h in 1% (w/v) BSA in PBS, 0.3% (v/v) Triton X-100. Then, cells were incubated with 1:200 lamin antibody (Santa Cruz Biotechnology) in 1.5% (w/v) BSA in PBS, 0.3% (v/v) Triton X-100 overnight at 4 °C. AlexaFluor 633 anti-rabbit IgG (Thermo Scientific, Waltham, MA, USA) was used as secondary antibody diluted 1:500 in PBS, 1% (w/v) BSA.

For phalloidin staining, cells were fixed in 3.7% (v/v) PFA in PBS for 10 min at room temperature and blocked in 1% (w/v) BSA, 0.05% (v/v) Triton X-100 in PBS for 30 min. Then, cells were incubated with Alexa 488-phalloidin (Molecular Probes, Invitrogen, Carlsbad, CA, USA) diluted 1:40 in 1% (w/v) BSA in PBS for 1 h at room temperature. Nuclei were counterstained by 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). Samples were examined by TCS SP2-Leica confocal microscope (Leica, Wetzlar, Germany).

3. Results and discussion {#s0055}
=========================

Fibroblasts are, along with osteoblasts and other derivatives of mesenchymal cells (*e.g.* chondroblasts, cementoblasts and odontoblasts), the major producers of collagen, and, as a consequence, they are among the main affected cells in collagen-related disorders. Since fibroblasts are the most abundant mesenchymal cells in the stroma of most tissues and organs, several tissues may be affected in OI.

Despite bone presents the main aberrances, OI extra-skeletal manifestations have been described. Beyond skin affections, blue sclerae and dentinogenesis imperfecta, also cardiovascular diseases, pulmonary defects, gastrointestinal manifestations, and skeletal muscle complications are reported in OI [@bb0040], [@bb0235], [@bb0240], [@bb0245].

According to these statements and to our previous analyses, we took advantage of fibroblast cells to investigate OI molecular basis. Protein 2-D profiles of skin primary fibroblasts obtained from control subjects and from patients carrying mutations in *CRTAP* (OI type VII), *P3H1* (OI type VIII), and *PPIB* (OI type IX) genes were compared applying a functional proteomic approach, consisting of 2-DE, mass spectrometry and dedicated bioinformatics tools for functional analysis.

We investigated fibroblast cells from 4 controls, 3 patients affected by OI type VII, 3 OI type VIII patients, and 1 OI type IX patient. OI type IX is quite rare, thus we were able to obtain fibroblasts from only one case [@bb0025], [@bb0155]. Fibroblasts from this unique type IX OI proband were anyway run in triplicate.

Representative silver stained electropherograms of control, *CRTAP*, *P3H1*, and *PPIB* fibroblast samples are reported in [Fig. 1](#f0005){ref-type="fig"}. Approximately 2000 spots were well detected in each gel from control and disease conditions with consistent experimental reproducibility. According to applied statistics, as described in [Material and methods](#s0010){ref-type="sec"}, 47 protein spots were found to differ in expression when control and pathological groups were compared. [Supplementary Table S1](#ec0005){ref-type="supplementary-material"} and Venn diagram, [Fig. S1](#ec0010){ref-type="supplementary-material"} (Supplementary material), detailed the six different performed pair comparisons and the corresponding detected ([Supp. Venn diagram](#ec0010){ref-type="supplementary-material"}) and identified differences ([Suppl. Table S1](#ec0005){ref-type="supplementary-material"}). Overall, 27 differentially expressed protein spots, which consists in 24 unique proteins, were successfully identified by MS, as summarized in [Supplementary Table S1](#ec0005){ref-type="supplementary-material"} and specified in [Table 1](#t0005){ref-type="table"}.Fig. 1Silver stained electropherograms of fibroblasts from control (A), *CRTAP* (B), *P3H1* (C), and *PPIB* (D) subjects. Numbers and circles visualize quantitative and/or qualitative significant differences detected among the analyzed conditions.Fig. 1.Table 1Differentially expressed protein spots identified by MS.Table 1:Spot n.Protein descriptionMetaCore name[a](#tf0005){ref-type="table-fn"}UniProt ID/name[b](#tf0010){ref-type="table-fn"}Mascot search resultsMean %V ± SD × 10^− 4^[c](#tf0015){ref-type="table-fn"}1-Way ANOVA p-valueScoreN. of matched peptidesSequence coverage (%)Control*CRTAPP3H1PPIBCytoskeletal and nuclear organization, and development*8CaldesmonCaldesmon[Q05682](uniprotkb:Q05682){#ir0005}/CALD119925/4629214 ± 203^§^[d](#tf0020){ref-type="table-fn"}664 ± 200^§¥\#^120 ± 160^¥^241 ± 49^\#^0.0123269Prelamin-A/CLamin A/C[P02545](uniprotkb:P02545){#ir0010}/LMNA13615/2522119 ± 68^\$^--20 ± 20^\$^35 ± 100.01235412Serine/threonine-protein kinase PAK 2PAK2[Q13177](uniprotkb:Q13177){#ir0015}/PAK214312/1733424 ± 97^⁎^228 ± 68426 ± 127^&^113 ± 59^⁎&^0.00787316FascinFascin[Q16658](uniprotkb:Q16658){#ir0020}/FSCN121421/4847380 ± 161------0.0006720Septin-11Septin 11[Q9NVA2](uniprotkb:Q9NVA2){#ir0025}/SEP11625/71071 ± 69^\$^--462 ± 218^\$^--0.00216425Annexin A2Annexin II[P07355](uniprotkb:P07355){#ir0030}/ANXA221618/2443101 ± 145^⁎^----402 ± 69^⁎^0.00221027Annexin A2Annexin II[P07355](uniprotkb:P07355){#ir0035}/ANXA222720/304863 ± 18----86 ± 410.00032634Rho GDP-dissociation inhibitor 1RhoGDI alpha[P52565](uniprotkb:P52565){#ir0040}/GDIR116915/33501437 ± 443^§^216 ± 58^§\#¥^1822 ± 393^¥^1345 ± 94^\#^0.00045641Ragulator complex protein LAMTOR3MP1[Q9UHA4](uniprotkb:Q9UHA4){#ir0045}/LTOR31527/86652 ± 2566 ± 1841 ± 7^&^101 ± 5^&^0.02941942Protein S100-A4MTS1 (S100A4)[P26447](uniprotkb:P26447){#ir0050}/S10A41157/11453909 ± 572^§^1234 ± 646^§¥^3774 ± 1387^¥^3155 ± 3670.005465  *Protein fate (synthesis, folding, proteolysis)*1Hypoxia up-regulated protein 1HYOU1[Q9Y4L1](uniprotkb:Q9Y4L1){#ir0055}/HYOU125535/6342561 ± 110^⁎§^187 ± 162^§^419 ± 71186 ± 151^⁎^0.00948317Heterogeneous nuclear ribonucleoprotein HhnRNP H1[P31943](uniprotkb:P31943){#ir0060}/HNRH115613/2137428 ± 92^§^1155 ± 96^§¥\#^175 ± 168^¥^176 ± 110^\#^0.02027418Heterogeneous nuclear ribonucleoprotein HhnRNP H1[P31943](uniprotkb:P31943){#ir0065}/HNRH119822/5559394 ± 154^§^1424 ± 75^§¥\#^238 ± 31^¥^141 ± 72^\#^0.02900523PDZ and LIM domain protein 1CLIM1[O00151](uniprotkb:O00151){#ir0070}/PDLI119717/3154412 ± 115^\$^313 ± 87148 ± 29^\$^325 ± 870.0257073026S proteasome non-ATPase regulatory subunit 8PSMD8[P48556](uniprotkb:P48556){#ir0075}/PSMD81047/91671 ± 54^⁎^133 ± 7979 ± 117332 ± 134^⁎^0.03999433Ubiquitin carboxyl-terminal hydrolase isozyme L1UCHL1[P09936](uniprotkb:P09936){#ir0080}/UCHL117311/2065237 ± 75^§^95 ± 16^§^230 ± 92116 ± 180.0280235Heat shock protein beta-1HSP27[P04792](uniprotkb:P04792){#ir0085}/HSPB11319/2257192 ± 198^⁎^361 ± 15185 ± 20^&^557 ± 97^&⁎^0.02048737Heat shock protein beta-1HSP27[P04792](uniprotkb:P04792){#ir0090}/HSPB1825/82889 ± 17^\$^77 ± 23^¥^29 ± 8^\$¥&^81 ± 10^&^0.006612LATQSNEITIPVTFESR3840S ribosomal protein S12RPS12[P25398](uniprotkb:P25398){#ir0095}/RS12966/114348 ± 1670 ± 19^¥^27 ± 6^&¥^79 ± 5^&^0.01093140Eukaryotic translation initiation factor 1b--[O60739](uniprotkb:O60739){#ir0100}/EIF1B835/154959 ± 42^⁎^68 ± 64^\#^--190 ± 9^⁎\#^0.017554  *Metabolism*11Pyruvate kinase PKMPKM2[P14618](uniprotkb:P14618){#ir0105}/KPYM1079/1419487 ± 120^§^1175 ± 319^§¥^227 ± 207^¥^--0.00045113Inosine-5′-monophosphate dehydrogenase 2IMD2[P12268](uniprotkb:P12268){#ir0110}/IMDH215713/1927797 ± 97328 ± 301^\#^534 ± 3061027 ± 19^\#^0.025709GKLPIVNEDDELVAIIAR14Succinyl-CoA:3-ketoacid coenzyme A transferase 1SCOT[P55809](uniprotkb:P55809){#ir0115}/SCOT112811/1924154 ± 112151 ± 178--400 ± 1170.04779115Aldehyde dehydrogenase X, mitochondrial--[P30837](uniprotkb:P30837){#ir0120}/AL1B116616/2630326 ± 61^⁎§\$^143 ± 97^§^172 ± 37^\$^63 ± 4^⁎^0.0060622Alcohol dehydrogenase \[NADP(+)\]ALDX[P14550](uniprotkb:P14550){#ir0125}/AK1A119516/3052382 ± 81210 ± 72--383 ± 760.00018629*S*-methyl-5′-thioadenosine phosphorylaseMTAP[Q13126](uniprotkb:Q13126){#ir0130}/MTAP16315/2548159 ± 41106 ± 39^\#^138 ± 49^&^264 ± 40^\#&^0.01323139Coiled-coil-helix-coiled-coil-helix domain-containing protein 5--[Q9BSY4](uniprotkb:Q9BSY4){#ir0135}/CHCH5965/96532 ± 23^⁎^27 ± 23^\#^--107 ± 53^⁎\#^0.009274[^2][^3][^4][^5]

3.1. Clusterization of differentially expressed proteins: hierarchical clustering {#s0060}
---------------------------------------------------------------------------------

Significant differentially expressed protein spots, independently on their successful identification by MS, were clustered by unsupervised hierarchical clustering (HC) based on their expression profiles in the 4 different tested conditions. The normalized mean-relative-volume (%V) values of all the proteins of interest were plotted against every analyzed sample set in order to highlight differences and similarities occurring among such protein spots, in relation to each tested condition (see [Material and methods](#s0010){ref-type="sec"}). HC results were visualized by expression matrix and dendrogram, and three main clusters were delineated: *clusters A*, *B*, and *C*, as shown in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Unsupervised Hierarchical Clustering (HC) analysis. Normalized %V mean values of significant differences, as computed in spot maps from control, *CRTAP*, *P3H1*, and *PPIB* cells, are visualized by expression matrix, where each represented %V value is proportional to color intensity, from black = zero expression to red = maximum positive expression. Spot identity (protein name, as listed in [Table 1](#t0005){ref-type="table"}, or number, for MS not identified spots) is annotated on the right of the expression matrix, while dendrogram of complete linkage clustering, based on centered correlation distance, is reported on the left. Main clusters are named from top to bottom and the corresponding expression profiles of their included proteins are shown on the right.Fig. 2.

*Cluster A* is the smaller obtained group containing only 5 significant protein differences whose expression profiles are similar in control, *P3H1*, and *PPIB* and different in *CRTAP* cells, where such proteins result up-regulated.

*Cluster B* includes 21 proteins that were further sub-clustered into 2 sub-groups: B.a and B.b. Mainly according to protein differential abundances in *P3H1* fibroblasts, the [sub-cluster B.a]{.ul} was additionally divided into B.a1 and B.a2. The 8 proteins from [B.a1]{.ul} show expression profiles similar in the three pathological conditions, with an evident down-regulation in respect to the control. [B.a2]{.ul} consists of 7 proteins under-expressed in *CRTAP* and *PPIB* patients. [Sub-cluster B.b]{.ul} comprises 6 differences whose expression profiles are similar in control, *CRTAP*, and *PPIB* but different in *P3H1* cells, where the highest expression was detected.

Also *cluster C* was divided into sub-clusters: C.a and C.b. While the 10 [C.a]{.ul} proteins show down-regulation in *CRTAP* and *P3H1* patients, the 11 [C.b]{.ul} differences display approximately similar expression in control, *CRTAP*, and *P3H1* and an up-regulation in *PPIB* fibroblasts.

As clearly represented by the [Fig. 2](#f0010){ref-type="fig"} expression matrix, HC highlighted a general down-regulation trend of protein spot differences in *CRTAP* mutants. Despite each pathological investigated condition showed a peculiar expression profile of protein differences, *CRTAP* and *P3H1* cells presented more similarities, well resembling CRTAP/P3H1 known mutual stabilization in rER [@bb0105].

The MS identified unique proteins were also classified according to DAVID HC (as detailed in [Material and methods](#s0010){ref-type="sec"}) and based on their main biological functions, as supported by scientific literature, into three main functional groups: i) cytoskeletal and nuclear organization and development, ii) protein fate (synthesis, folding, and proteolysis), and iii) metabolism, as indicated in [Table 1](#t0005){ref-type="table"}. Those functional groups were also delineated in our previous work on dominant OI to cluster proteins changing in expression among Brtl^+/−^ mice and wild-type littermates [@bb0095].

Reported findings interestingly indicate that, despite the majority of deregulated proteins identified in dominant and recessive OI forms are different, specific biological processes and molecular functions are characteristically affected in OI, independently of Mendelian mode of transmission and of mutated gene.

3.2. Clusterization of differentially expressed proteins: functional groups {#s0065}
---------------------------------------------------------------------------

Identified differentially expressed proteins were clustered based on all their characterizing GO terms. Besides "biological process", also "molecular function" and "cellular component" GO terms, along with literature text mining, were taken into account and 5 functional groups were delineated: i) cytoskeletal and nuclear organization, ii) development and cell adhesion, iii) protein fate (synthesis, folding, proteolysis), iv) apoptosis, and v) metabolism, as shown in [Fig. 3](#f0015){ref-type="fig"}. i) and ii) were the main represented functional groups including 11 ([Fig. 3](#f0015){ref-type="fig"}: dark pink bar) and 13 ([Fig. 3](#f0015){ref-type="fig"}: blue bar) proteins, respectively. iii) grouped 9 proteins ([Fig. 3](#f0015){ref-type="fig"}: green bar), as well as iv) ([Fig. 3](#f0015){ref-type="fig"}: light blue bar), and v) comprised 8 proteins ([Fig. 3](#f0015){ref-type="fig"}: orange bar). More than half of the identified unique proteins resulted involved in multiple biological functions, cytoskeleton and nucleoskeleton, and development and cell adhesion appeared as the most affected structures and processes in recessive OI.Fig. 3Histogram from a five-way Venn diagram of functional clustering of the MS identified unique proteins. The histogram displays the number of unique proteins, listed below each bar, in every delineated functional cluster, according to all the GO terms characterizing differentially expressed proteins (*i.e.* biological process, molecular function, and cellular component).Fig. 3.

This functional clustering, despite the small number of proteins found differentially expressed, may account for relevant pathways altered in OI. Indeed, the few aberrantly expressed multifunctional factors that we identified may lead to a simultaneous affection of several pathways determining loss of cell and tissue functionality and homeostasis. Moreover, those "moonlight" proteins act key roles in pathways that are known, or at least hypothesized, to be relevant in OI pathogenesis, as later discussed.

3.3. Pathway analysis {#s0070}
---------------------

In order to functionally correlate the identified proteins, MetaCore pathway analysis was performed applying the shortest path algorithm [@bb0250]. Only proteins closely related in function were indeed included into the generated networks. About 90% of MS identified proteins clustered into the most relevant of the generated nets ([Fig. 4](#f0020){ref-type="fig"}: blue circles; [Table 1](#t0005){ref-type="table"}), thus demonstrating the significance of produced data and, particularly, of the biological meaning of their altered expression.Fig. 4MetaCore protein network. MetaCore analysis was used to map identified proteins (blue circles) on existing mammalian pathways and networks, according to known protein-protein interactions and other features established in the literature. Network proteins are visualized by specific symbols, which define the functional nature of the protein (network caption). The edges indicate the relationships existing between individual proteins, and the arrowheads represent the direction of the interaction. The following line colors designate the nature of the interaction: red = negative effect; green = positive effect; gray = unspecified effect. Based on selected parameters, only eukaryotic translation initiation factor 1b (EIF1B), coiled-coil-helix-coiled-coil-helix domain-containing protein 5 (CHCHD5), and aldehyde dehydrogenase X, mitochondrial (AL1B1) were excluded from the net.Fig. 4.

Studying the network, identified multifunctional proteins that here represent the main central hubs, *i.e.* heat shock protein beta-1 (HSP27), pyruvate kinase PKM (PKM2), lamin A/C, serine/threonine-protein kinase PAK 2 (PAK2), and protein S100A4 (MTS1), focused the attention mainly on cytoskeleton and nucleoskeleton organization. A higher level of complexity in interpreting this result was related to the MetaCore-added and not-experimentally-detected factors. Their tight crosstalk with experimental hubs delineated complex pathways that unambiguously correlate cytoskeleton and nucleoskeleton to development, differentiation and functionality of organs and apparatus usually affected in OI. Actually, several of those not-experimental-detected factors directly control or are controlled by the above reported central hubs and they have key functions in regulating signal transduction and transcription during development, cell proliferation, differentiation, survival, and apoptosis. Moreover, most of them are transcription factors whose detection is usually difficult in 2-D gels since their levels relay under the limits of detection by conventional staining protocols.

More in detail, besides the almost pleiotropic proteins c-Myc, p53, Oct-3/4, all described in Bianchi et al. [@bb0095], Nanog, and Sox2, whose altered expression affect development in several tissues, the transcriptional factors NF-kB and KLF4 operate in signaling pathways whose proper and balanced regulation is essential for normal bone and tooth development and remodeling [@bb0255], [@bb0260], [@bb0265], [@bb0270], [@bb0275], [@bb0280]. Of relevance, altered NF-kB function has been described in genetic disorders, such as ectodermal dysplasias (ED), that impair, as well as OI, skin, eye, inner ear, limbs and bone [@bb0285]. NF-kB signaling is known to depend or to intersect signal transduction of the two fundamental bone regulators: TGF-β and BMPs, being it activated by TGF-β/BMP non-canonical pathway or interfering with Smad signaling, respectively [@bb0290], [@bb0295], [@bb0300]. Moreover, Smad2/3, which are two other transcription factors added by the software, were previously proved, along with TGF-β, as altered in dominant OI [@bb0145], [@bb0305].

Smad and NF-kB interestingly emerged as critical factors for osteoblast differentiation and for bone mass regulation by intersecting Wnt/β-catenin pathway [@bb0310], [@bb0315]. Once again, β-catenin is a MetaCore-added factor interconnected with the main central hubs of the net. Wnt/β-catenin and TGF-β/BMP signaling are known to regulate each other and to cooperate in controlling fibroblast and osteoblast collagen production [@bb0320], [@bb0325], [@bb0330], [@bb0335]. Dysfunctions of such pathways are related to fibrosis and aberrances in bone formation and wound healing [@bb0330], [@bb0340], [@bb0345], [@bb0350], with this latter being one of the main cause of skeletal deformity in OI. Interestingly, mutations in *WNT1*, which is a regulator of canonical Wnt-signaling [@bb0355], [@bb0360], are causative of recessive OI [@bb0365], [@bb0370].

TGF-β/BMP non-canonical pathway also controls another MetaCore-added protein: AP-1, which is known to operate in bone disruption/formation [@bb0375] and that is linked to all the central hubs of the generated net, except for PKM2.

Still in line with TGF-β/BMP and Wnt/β-catenin but also with integrin and cadherin cascades, which are all fundamental in skeletal and skin development and that are reported to crosstalk each other [@bb0380], the software generated the net including also AKT, ERK1/2 and p300. They properly fit into the MetaCore-delineated signaling interconnection and into the induced responses by exerting key roles in the above listed pathways [@bb0320], [@bb0325], [@bb0380], [@bb0385].

Finally, the not-experimentally detected HIF-1 protein directly controls the experimentally detected fascin, S100A4, and annexin II, all factors operating in cytoskeleton dynamics and bone metabolism. HIF-1 is necessary for embryogenesis, physiological development of several organs (*e.g.* bone, lung and heart), and tissue remodeling/healing. Defects in hypoxia/HIF-1 signaling lead to anomalies in skeletal, cardio-vascular and respiratory systems [@bb0390], [@bb0395], [@bb0400]. Accordingly, OI probands develop, in addition to bone aberrances, cardio-vascular defects and pulmonary affections [@bb0040], [@bb0235], [@bb0405].

3.4. MetaCore central hubs: nucleoskeleton and cytoskeleton affection {#s0075}
---------------------------------------------------------------------

Despite several of the main protein-actors on the stage of OI morbidity differ between dominant and recessive forms, shared clinical features in different OI types suggest common molecular pathomechanisms at the bases of this disorder. Our functional proteomic study has evidenced, once more, that cytoskeletal anomalies characterized OI cells and that they may contribute to OI pathogenesis. Here we also proved, for the first time, the occurrence of altered nucleoskeleton in recessive OI by having detected aberrances in lamin A/C expression and organization in the nucleus. Interestingly lamin A/C was included in the above described cluster B.a1, where proteins sharing similar expression in all patients were grouped.

Lamins are nuclear type V intermediate filaments [@bb0410]. They are the principal component of the nucleoskeleton and their main function is to provide shape, stiffness and architecture to the nucleus. Lamins are deeply involved in chromatin organization and gene expression, as well as in DNA replication and repair, thus concurring to cell signaling, proliferation, migration and differentiation [@bb0415], [@bb0420], [@bb0425]. Lamin A and C are A-type lamins derived by alternative splicing of the *LMNA* gene. Both these isoforms are equally present in mammalian lamina, the fibrous protein meshwork located just underneath the inner nuclear membrane [@bb0430]. Lamin A/C is developmentally regulated and mainly expressed in differentiated cells [@bb0420]. Of relevance, several studies demonstrated the crucial role of lamin A/C in osteoblastogenesis and bone formation, *in vitro* and *in vivo*. While in osteogenic differentiating human mesenchymal stem cells (MSCs) the loss of lamin A/C inhibits osteoblast differentiation and mineralization [@bb0435], [@bb0440], in mature osteoblast it leads to a reduced mineralization and alkaline phosphatase expression, thus suggesting that lamin A/C is required for both MSC commitment and for mature osteoblast physiological functions [@bb0435]. On the other hand, inhibition of lamin A/C facilitates the differentiation of human MSCs into adipocytes [@bb0435]. Interestingly, MSCs from adult Brtl^+/−^ mice have a reduced osteogenic potential and an increased ability to differentiate toward adipocytes [@bb0445], as well as it was observed in PEDF knock-out mouse, a model of recessive OI that showed enhanced adiposity and decreased bone mineral content [@bb0450].

Of great relevance to correlate the lamin aberrancy that we detected to OI traits, mice lacking lamin A/C or enzymes involved in its processing present a bone phenotype very similar to those observed in dominant and recessive OI patients and murine models. *Lmna*^−/−^ mice actually display a severe osteopenic phenotype with significant decrease in bone mass and bone apposition, and with poor bone microarchitecture [@bb0455]. Also *Zmpste24*^−/−^ mice, which lack zmpste24 enzyme for lamin A/C processing, show an osteopenic phenotype with brittle bones and spontaneous bone fractures [@bb0460]. In transgenic mice, which resemble the Hutchinson-Gilford progeria syndrome (HGPS), the bone phenotype is reverted by completely silencing endogenous mutated *Lmna* gene and inducing transgenic expression of human lamin A/C [@bb0465].

*LMNA* mutations or incorrect processing of lamin A/C are causative of a wide spectrum of human heterogeneous diseases termed laminopathies [@bb0470], several of which share some features with OI. Certain forms of laminopathies affect different adipose and bone tissues [@bb0475], with MAD (mandibuloacral dysplasia) and HPGS presenting the main bone and dental affections (*i.e.* osteoporosis, osteolysis, bone and dental deformities, and spontaneous fractures) [@bb0480], [@bb0485], [@bb0490], [@bb0495].

After its identification among protein spots that significantly change in abundance ([Table 1](#t0005){ref-type="table"}: spot n. 9), we proved lamin A/C aberrant protein-expression in recessive OI performing 2-D western blot. As shown in [Fig. 5](#f0025){ref-type="fig"}A, fibroblasts from *CRTAP* and *P3H1* patients show an evident increased immunoreactive signal of lamin C protein species (isoelectric series at lower MW) when compared to the control cells. On the other hand, *P3H1* fibroblasts present depleted signals of lamin A protein species (isoelectric series at higher MW; [Fig. 5](#f0025){ref-type="fig"}A) with respect to control and *CRTAP* cells, which instead have a similar intensity. Fibroblasts from the *PPIB* proband are discordant with the other investigated cells displaying a dramatic reduction of both lamin A and C.Fig. 5Lamin A/C protein abundance (A) and nuclear organization in human dermal fibroblasts from control subjects and OI patients with mutations in *CRTAP*, *P3H1*, and *PPIB* genes (B). A: Representative 2-D western blot images are shown. Histograms visualize the total spot Vol of each isoelectric series: lamin A in dark gray and lamin C in light gray. B: Representative confocal immunofluorescence images are shown. Lamin A/C signal is shown in red. Counterstaining of the nuclei was performed using DAPI (blue). An altered lamin distribution was detected in all pathological primary cells. Scale bar 10 μm.Fig. 5.

These data suggested the occurring of nuclear lamina and nucleoskeleton disorganization. To evaluate eventual correlated nuclear aberrances, a confocal immunofluorescence analysis for lamin A/C was indeed performed on fibroblasts from all the four analyzed conditions. As illustrated in [Fig. 5](#f0025){ref-type="fig"}B, lamin A/C homogenously distributed at the nuclear periphery of control cells. On the contrary, recessive OI fibroblasts displayed lamin A/C staining not only peripherally but also throughout the nucleoplasm where lamin A/C foci were also detected ([Fig. 5](#f0025){ref-type="fig"}B: arrows), thus suggesting the occurrence of lamin fibers accumulation in some restricted areas. Interestingly, aberrant lamin A/C organization and intranuclear foci presence were described in fibroblasts from patients affected by different laminopathies, as well as in human transfected fibroblasts and myoblasts expressing mutant lamin A/C [@bb0500], [@bb0505], [@bb0510]. Furthermore, *CRTAP*, *P3H1*, and *PPIB* fibroblasts presented a lamin A/C "granular aspect" resembling the lamin A/C "honeycomb" pattern observed in nuclei from laminophatic cells [@bb0500], [@bb0515], [@bb0520], [@bb0525].

Why different genetic disorders, caused by different mutated genes whose protein products act in different and (apparently) not overlapping pathways, present similar aberrances is still puzzling. On the bases of our data, nucleoskeleton and cytoskeleton affection may intriguingly represent a molecular bridge between OI and other apparently not related diseases, such as laminopathies. Alterations in nucleoskeleton, actually, negatively affect the cytoskeleton organization and cytoskeleton aberrances determine nucleoskeleton, and chromatin, affection [@bb0530], [@bb0535], [@bb0540].

A-type lamins anchor nucleoskeleton to cytoskeleton and indirectly regulate cytosolic actin assembly [@bb0545], [@bb0550]. Such cytoskeleton/nucleoskeleton interactions act as sensors and transducers of signals from the cytoplasm to the nucleus, and *vice versa*, to regulate nuclear position, gene expression, and cell functions [@bb0555]. In turn, the cytoskeleton is connected to the ECM *via* focal adhesion (FA) integrins [@bb0560]. Of note, abnormal ECM composition, which is a hallmark of OI [@bb0040], was reported in lipodystrophy and in model cell lines of Hutchinson-Gilford Progeria (HGPS), as linked, respectively, to altered TGF-β and Wnt signaling [@bb0565], [@bb0570]. To close the circle, lamins indirectly interfere with TGF-β and Wnt signaling by regulating the inner nuclear membrane integral proteins MAN1, which inactivate Smads, and emerin that mediates the nuclear export of β-catenin [@bb0575], [@bb0580], [@bb0585], [@bb0590].

Our data suggest an alteration of the tight interconnection among nucleus, cytoskeleton and ECM in OI cells, and their strong cooperation in sensing, integrating, and transducing extracellular stimuli for cell response [@bb0595] may represent a molecular link between OI and other disorders, such as laminopathies.

Based on the here proved aberrant organization of nuclear lamina, on the high percentage (46%) of differentially expressed proteins involved in cytoskeleton asset, on the MetaCore built network, and, finally, on previous data from dominant forms of the disease [@bb0145], we hypothesized that also cytoskeleton was affected in investigated fibroblast cells. Cofilin-1 protein abundance levels were evaluated to assess cytoskeleton "health status" in *CRTAP*, *P3H1*, and *PPIB* fibroblast samples by using 1-D western blot. Cofilin-1 was chosen as it is an essential regulator of actin dynamics, by inducing F-actin depolymerization and inhibiting G-actin polymerization [@bb0600], and on the bases of its proved deregulation in a murine model of dominant OI [@bb0095], [@bb0145]. Very recently, Wiggan *et al.* have also described cofilin-1 to indirectly regulate nuclear architecture and as its deregulation, along with ADF (actin-depolymerizing factor or destrin), provokes consistent nuclear lamina disruption and aberrant chromatin organization [@bb0605]. In addition, the MetaCore processing of cofilin-1 with the differentially expressed proteins generated, by shortest path, a significant network where this G- and F-actin modulator was perfectly integrated, [Supplementary Fig. S2](#ec0015){ref-type="supplementary-material"}. Consistent with previously described data in dominant OI [@bb0145], we found a statistically significant increase of cofilin-1 in fibroblasts from *CRTAP* and *P3H1* patients, [Fig. 6](#f0030){ref-type="fig"}A. Despite it was not statistically significant, an increase of cofilin-1 was detected also in *PPIB* cells.Fig. 6Cofilin-1 protein abundance (A) and cytoskeletal organization in human dermal fibroblasts from OI patients (B). A: Representative 1-D western blot images are shown. Histograms visualize normalized mean relative-integrated density ± SD values of detected bands. \* and § symbols indicate the significance of expression changes occurring between control and *CRTAP*, and control and *P3H1* fibroblasts, respectively. B: Representative confocal immunofluorescence images are shown. Fluorescently labeled phalloidin (green), specifically interacting with actin, was used. Counterstaining of the nuclei was performed using DAPI (blue). A disorganized cytoskeletal network was evident in all patients primary cells. Scale bar 10 μm.Fig. 6.

Then, to verify the presence of cytoskeletal anomalies, a confocal immunofluorescence analysis was performed on fibroblasts from controls and probands by using the fluorescently labeled phalloidin, which specifically targets actin. A disorganized cytoskeleton, with an abnormal distribution of actin fibers, was revealed, [Fig. 6](#f0030){ref-type="fig"}B. This finding maybe reflects the tight structural/functional coupling of nucleoskeleton to cytoskeleton.

The relevance of actin cytoskeleton in osteoblast differentiation and bone development has been largely discussed in our previous work on dominant OI [@bb0145]. It has been even demonstrated that cell viability and differentiation of human MSCs into osteoblasts are enhanced by stabilizing actin filaments through cofilin-1 and destrin inhibition, while the opposite effect was achieved silencing the cofilin-1 inhibitor LIMK1 [@bb0610], [@bb0615]. Noteworthy, we identified two differentially expressed proteins involved in LIMK1 activity control: p21-activated kinase 2 (PAK2) and Rho GDP-dissociation inhibitor 1 (RHOGDI1 or RHOGDIα). PAK2, one of the main central hubs in the MetaCore generated network, is a downstream effector of Rho small GTPases that phosphorylates and activates LIMK1 [@bb0620] and that is known to operate in many cellular processes depending on cytoskeleton dynamics [@bb0625]. RHOGDI1, instead, regulates several Rho GTPases, such as Cdc42, preventing the release of GDP [@bb0630]. PAK2 controls, by a positive feedback, its own activation inhibiting RHOGDI1 and maintaining the active state of Cdc42, which in turn activates PAK2 [@bb0635], as highlighted in [Fig. 4](#f0020){ref-type="fig"}. PAK2 decreased in *CRTAP* and *PPIB* fibroblasts, [Table 1](#t0005){ref-type="table"}, spot 12. In these patients, PAK2 down-regulation may lead to a reduced LIMK1 activity and to altered cytoskeleton dynamics.

4. Conclusions {#s0080}
==============

In this work, we reported for the first time nucleoskeleton and cytoskeleton aberrances in recessive OI forms characterized by collagen structural defects. We also highlighted, according to our previous analyses, that specific biological processes and molecular functions, mainly related to cytoskeleton and nucleoskeleton, are similarly affected in dominant and recessive OI, independently of their different protein abundance profiles and mutated genes. We indeed believe that nucleus and cytoskeleton organization may represent novel targets to develop innovative treatment for OI.

The tight interconnection among nucleus, cytoskeleton, and ECM and their strong cooperation in sensing, integrating, and transducing stimuli for cell response [@bb0595] may represent a molecular bridge among different diseases.

In line with this concept, some of the molecular pathways that we hypothesized, according to our data, to be aberrant in OI have been previously described as affected also in laminopathies. Despite their distinctive etiology and phenotypic features, OI and laminopathies present affection of nuclear lamina and cytoskeleton, and of TGF-β, integrin and Wnt signaling, even though such aberrances occur in response of different trigger events.

In conclusion, the comparison of aberrant molecular pathways that characterize different forms of the same disorder or different disorders, caused by different mutated genes, may pave the way to a molecular reviewing of diseases based on similarities in molecular affection. Such perspective may flank conventional clinical practice as well as pharmacological approach by suggesting novel drug targets.

The following are the supplementary data related to this article.Table S1Detected quantitative and qualitative differences in the six different performed pair comparisons.Table S1:Supplementary Fig. S1Six-way Venn diagram (A), displayed by Edwards\' mode, and histogram (B) of the quantitative and qualitative differentially expressed protein-spots detected by crossed comparisons among control subjects and OI patients carrying mutations in *CRTAP*, *P3H1*, and *PPIB* genes. A and B show distribution of common and peculiar differences in the six performed pair-comparisons.Supplementary Fig. S1Supplementary Fig. S2MetaCore protein network obtained by processing cofilin-1 with the differentially expressed proteins in primary fibroblasts from *CRTAP*, *P3H1*, and *PPIB* patients and from control subjects. MetaCore analysis was used to map identified proteins (blue circles) on existing mammalian pathways and networks, according to known protein-protein interactions and other features established in the literature. Network proteins are visualized by specific symbols, which define the functional nature of the protein (network caption). The edges indicate the relationships existing between individual proteins, and the arrowheads represent the direction of the interaction. The following line colors designate the nature of the interaction: red = negative effect; green = positive effect; gray = unspecified effect. Based on selected parameters, only eukaryotic translation initiation factor 1b (EIF1B), coiled-coil-helix-coiled-coil-helix domain-containing protein 5 (CHCHD5), and aldehyde dehydrogenase X, mitochondrial (AL1B1) were excluded from the net.Supplementary Fig. S2Supplementary materialImage 1
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